Cargando…

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

BACKGROUND: Baseline clinical variables are prognostic for overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). Their prognostic and predictive value with agents targeting bone metastases, such as radium-223, is not established. PATIENTS AND METHODS: The radium-223 ALS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sartor, O., Coleman, R. E., Nilsson, S., Heinrich, D., Helle, S. I., O’Sullivan, J. M., Vogelzang, N. J., Bruland, Ø., Kobina, S., Wilhelm, S., Xu, L., Shan, M., Kattan, M. W., Parker, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406754/ https://www.ncbi.nlm.nih.gov/pubmed/28453701 http://dx.doi.org/10.1093/annonc/mdx044

Ejemplares similares

Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA
por: Sartor, Oliver, et al.
Publicado: (2016)

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
por: Nilsson, S., et al.
Publicado: (2016)

Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial
por: Heidegger, Isabel, et al.
Publicado: (2018)

Insights into the prognostic potential of total alkaline phosphatase in metastatic castration-resistant prostate cancer treated with radium-223
por: Viani, Gustavo
Publicado: (2023)

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
por: van der Doelen, Maarten J., et al.
Publicado: (2021)

SERUM VALUES OF ALKALINE PHOSPHATASE AND LACTATE DEHYDROGENASE IN OSTEOSARCOMA
por: ZUMÁRRAGA, JUAN PABLO, et al.
Publicado: (2016)

Radium-223 and bone metastatic disease: still more to learn
por: Sartor, Oliver
Publicado: (2023)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

SERUM VALUES OF ALKALINE PHOSPHATASE AND LACTATE DEHYDROGENASE IN EWING'S SARCOMA
por: Baptista, André Mathias, et al.
Publicado: (2016)

Pre-treatment serum lactate dehydrogenase and alkaline phosphatase as predictors of metastases in extremity osteosarcoma
por: Marais, Leonard C., et al.
Publicado: (2015)

Radium-223 and concomitant therapies: prospects and prudence
por: Yeku, Oladapo, et al.
Publicado: (2016)

Radium 223 dichloride for prostate cancer treatment
por: Deshayes, Emmanuel, et al.
Publicado: (2017)

Patient selection and treatment response assessment in radium-223 therapy
por: Kay, M, et al.
Publicado: (2015)

Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer
por: Chen, Bo, et al.
Publicado: (2016)

Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015)

Current approaches to incorporation of radium-223 in clinical practice
por: Parker, Chris, et al.
Publicado: (2018)

Imaging and dosimetry for radium-223: the potential for personalized treatment
por: Flux, Glenn D
Publicado: (2017)

An assessment of combined tumour markers in patients with seminoma: placental alkaline phosphatase (PLAP), lactate dehydrogenase (LD) and beta human chorionic gonadotrophin (beta HCG).
por: Munro, A. J., et al.
Publicado: (1991)

Prognostic value of combined preoperative lactate dehydrogenase and alkaline phosphatase levels in patients with resectable pancreatic ductal adenocarcinoma
por: Ji, Fei, et al.
Publicado: (2016)

Evaluation of Lactate Dehydrogenase and Alkaline Phosphatase as Predictive Biomarkers in the Prognosis of Hepatocellular Carcinoma and Development of a New Nomogram
por: Su, Ke, et al.
Publicado: (2023)

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
por: Heidenreich, Axel, et al.
Publicado: (2019)

Radium-223 Treatment in mCRPC Patient with Polycythemia Vera
por: de Angelis, Cristina, et al.
Publicado: (2021)

Ocular complications with the use of radium-223: a case series
por: Bloom, Julie R., et al.
Publicado: (2022)

Diagnostic evaluation of milk lactate dehydrogenase and alkaline phosphatase activities by receiver operating characteristic analysis curve in early lactation of ewes with subclinical mastitis
por: Narenji Sani, Reza, et al.
Publicado: (2018)

Comparison of Analytical Values after Changing to the International Standardized Method for Lactate Dehydrogenase and Alkaline Phosphatase Measurements in Mouse and Rat
por: Furumoto, Kayo, et al.
Publicado: (2022)

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer
por: Cox, Heather, et al.
Publicado: (2015)

Analysis of Unusual Adverse Effects After Radium-223 Dichloride  Administration
por: Frantellizzi, Viviana, et al.
Publicado: (2020)

Clinical aspects of mCRPC management in patients treated with radium-223
por: Rizzini, Elisa Lodi, et al.
Publicado: (2020)

Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223
por: Hijab, Adham, et al.
Publicado: (2021)

Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2017)

A Study to Analyze the Alkaline Phosphatase and Lactate Dehydrogenase Enzyme Activity in Gingival Crevicular Fluid During Orthodontic Tooth Movements
por: Kumar, Barun Dev, et al.
Publicado: (2022)

Clinical outcomes, management, and treatment patterns in patients with metastatic castration‐resistant prostate cancer treated with radium‐223 in community compared to academic settings
por: Sartor, Oliver, et al.
Publicado: (2021)

Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer
por: O’Sullivan, Joe M., et al.
Publicado: (2022)

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
por: Fong, Lawrence, et al.
Publicado: (2021)

223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy
por: Anderson, Pete M, et al.
Publicado: (2020)

Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
por: Lien, Lise Marie E, et al.
Publicado: (2015)

Real-Time Scintigraphic Assessment of Intravenous Radium-223 Administration for Quality Control
por: Wright, Chadwick L., et al.
Publicado: (2015)

Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold
por: Aprile, Carlo, et al.
Publicado: (2016)

Analysis of hematological parameters as prognostic markers for toxicity and survival of (223)Radium treatment
por: Leisser, Asha, et al.
Publicado: (2018)

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
por: Du, Yong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_novmna2sqe0nom8uakc7mvrvtb